Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A2P4LJ5
Thu, 14.11.2024
PharmaSGP Holding SE
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised
Gräfelfing, November 14, 2024 – In the third quarter of 2024, the German OTC pharmaceutical company PharmaSGP Holding SE was able to continue the dynamic business development of the first half of the year, generating revenues of €88.6 million in the first nin [ … ]
Tue, 05.11.2024
PharmaSGP Holding SE
CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
Gräfelfing, November 05, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is announcing a change in the position of Chief Executive Officer (CEO). After more than seven years as CEO, Natalie Weigand informed the Supervisory Board today [ … ]
Tue, 05.11.2024
PharmaSGP Holding SE
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January [ … ]
Tue, 01.10.2024
PharmaSGP Holding SE
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
PharmaSGP Holding SE has purchased 477,701 own sha [ … ]
Thu, 12.09.2024
PharmaSGP Holding SE
PharmaSGP continues dynamic growth path in the first half of 2024
Gräfelfing, September 12, 2024 – The German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic growth path in the first half of 2024, achieving half-year revenues of €58.4 million based on preliminary, unaudited figures. This represents an increase of 17.4% compa [ … ]
Thu, 12.09.2024
PharmaSGP Holding SE
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE AD-HOC RELEASE.
Disclosure of an inside information acc. to Art. 17 [ … ]
Thu, 27.06.2024
PharmaSGP Holding SE
PharmaSGP Holding SE: Annual General Meeting approves full distribution of the Group’s profit for 2023 following a successful business performance
89.74% of the share capital was represented; all agenda items were approved
Shareholders approve increased dividend distribution of €1.36 per dividend-bearing share
The appointment of Peter Gerckens [ … ]
Fri, 21.06.2024
PharmaSGP Holding SE
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
PharmaSGP expands the Management Board as of July 1, 2024 with Peter Gerckens as Chief Commercial Officer (CCO), a newly created position
Peter Gerckens will be responsible for international markets, sales and new businesses
Gräfelfing, June 21, 2024 – German OTC p [ … ]
Tue, 14.05.2024
PharmaSGP Holding SE
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
Gräfelfing, May 14, 2024 – German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to €30.1 million (prior-year quarter: €24.0 mil [ … ]
Thu, 18.04.2024
PharmaSGP Holding SE
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
Gräfelfing, April 18, 2024 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5) will propose to this year's Annual General Meeting [ … ]